SCHEMBL2869730

SCHEMBL2869730

CCN(CC)CCNC(=O)C1CNCC2C(=O)OC(c3ccccc3)(c3ccccc3)N12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.43
TACR1 P25103 2/20 0.39
ALDH1A1 P00352 2/20 0.38
ALOX15 P16050 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 2/20 0.37
HPGD P15428 1/20 0.37
STAT3 P40763 1/20 0.37
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
CHRM2 P08172 1/20 0.36
POLB P06746 2/20 0.35
P4HB P07237 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
GLA P06280 1/20 0.35
GFER P55789 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2858351 0.92 SIGMAR1 (0.37) SIGMAR1TACR1ALDH1A1ALOX15NPSR1
Hydrochloric Acid SCHEMBL2869159 0.88 NPSR1 (0.35) SIGMAR1TACR1ALDH1A1ALOX15NPSR1
SCHEMBL2868400 0.84 OPRL1 (0.37) TACR1ALDH1A1ALOX15NPSR1HPGD
SCHEMBL2864536 0.84 MC4R (0.46) ALDH1A1NPSR1TP53POLB
SCHEMBL2863451 0.83 NPSR1 (0.36) ALDH1A1NPSR1KDM4EPOLB
SCHEMBL2860998 0.83 NPSR1 (0.41) TACR1NPSR1POLBTSHR
SCHEMBL2864640 0.82 NPSR1 (0.38) NPSR1HPGDTSHR
SCHEMBL2872946 0.82 NPSR1 (0.34) ALDH1A1NPSR1TSHRGFER
SCHEMBL2862082 0.82 HTR4 (0.43) SIGMAR1NPSR1POLBTSHR
SCHEMBL2868696 0.82 SIGMAR1 (0.44) SIGMAR1NPSR1BCHEACHEPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 SIGMAR1 71/4885TACR1 49/4885ALDH1A1 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.